



Ivermectin [HRP] (DAG1207)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Product Overview	Ivermectin, HRP conjugate
Antigen Description	Anthelmintics or anti-helminthics are a class of drugs that are effective against a range of intestinal parasitic worms (helminths). Parasitic helminths must maintain an appropriate feeding site. Nematodes and trematodes must actively ingest and move food through their digestive tracts to maintain an appropriate energy state; these together with reproductive processes require a well defined and developed neuromuscular coordination. Anthelmintic treatment is a multi-targeting system designed to interfere with the integrity of parasite cells. The pharmacologic basis of the treatment for helminths involves the targeting of neuromuscular coordination, or protective mechanisms against host immunity, which lead to starvation, paralysis, and expulsion of the parasite. The benzimidazole class of drugs were introduced in 1961 and interfere with the parasite's ATP pathway on a cellular level. They bind to a specific building block called b-tubulin and prevent its incorporation into certain cellular structures called microtubules, which are essential for energy metabolism.
Species	N/A
Conjugate	HRP
Applications	ELISA, Immunoassays, Development of Rapid tests and other immunoassay, antibody recognition assays
Format	Concentrate
Size	0.5 ml
Preservative	None
Storage	2-8°C short term, -20°C long term

BACKGROUND

45-1 Ramsey Road, Shirley, NY 11967, USA

Email: info@creative-diagnostics.com

Tel: 1-631-624-4882 Fax: 1-631-938-8221

Introduction

Ivermectin (22,23-dihydroavermectin B1a + 22,23-dihydroavermectin B1b) is a broad-spectrum antiparasitic drug in the avermectin family. It is sold under brand names Heartgard, Sklice, and Stromectol in the United States, Ivomec worldwide by Merial Animal Health, Mectizan in Canada by Merck, and Ivexterm in Mexico by Valeant Pharmaceuticals International. In Southeast Asian countries, it is marketed by Delta Pharma Ltd. under the trade name Scabo 6. While in development, it was assigned the code MK-933 by Merck.

Keywords

Ivermectin